PANACEABIONSEPanacea Biotec Limited· PharmaceuticalsMediumNegative
Announced Fri, 27 Mar · 17:40 IST

Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Litigation LossRegulatory & Legal View source PDF

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.9%1-day move
₹318.80
prior close
₹313.65
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-0.2+0.6+1.9+2.9+1.0+1.0+0.4+4.4+2.3+11.1+13.5+24.9+78.9
Up moveDown movePending
AI summary

Panacea Biotec has informed the exchanges that the Commissioner of Income Tax (Appeals), New Delhi, has dismissed all three appeals filed by the company against penalty orders issued by the Assistant Commissioner of Income Tax. The original penalty orders (dated December 24, 2025) were for alleged under-reporting of income across assessment years 2017-18, 2020-21, and 2021-22, with a total demand of approximately ₹9.38 Crore. The company believes the demand is not maintainable and plans to file a further appeal with a higher appellate authority. The company has stated it does not foresee any material impact on its financial position, operations, or other activities.

Likely market impact

While the appellate body ruled against the company at the first level of appeal, the management maintains confidence in challenging the demand further and sees no operational or financial impact. Investors should monitor the next round of appeal proceedings, as a final adverse ruling could result in an outgo of up to ₹9.38 Crore, though the company has signaled it intends to contest vigorously.